NASDAQ:CRTX - Cortexyme Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $128.00
  • Forecasted Upside: 36.68 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$93.65
▲ +1.5 (1.63%)

This chart shows the closing price for CRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cortexyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRTX

Analyst Price Target is $128.00
▲ +36.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $128.00, with a high forecast of $200.00 and a low forecast of $34.00. The average price target represents a 36.68% upside from the last price of $93.65.

This chart shows the closing price for CRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Cortexyme. This rating has held steady since April 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2021Canaccord GenuityBoost Price TargetBuy$75.00 ➝ $150.00High
8/26/2021HC WainwrightReiterated RatingPositive ➝ Buy$76.00 ➝ $200.00High
8/9/2021HC WainwrightReiterated RatingBuy$76.00High
2/16/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $34.00Low
12/11/2020Smith Barney CitigroupInitiated CoverageSellHigh
12/7/2020Bank of AmericaUpgradeNeutral ➝ BuyMedium
9/24/2020Lifesci CapitalReiterated RatingOutperformHigh
6/24/2020HC WainwrightInitiated CoverageBuy$76.00High
6/2/2020Jefferies Financial GroupInitiated CoverageBuy$59.00Low
5/13/2020Canaccord GenuityReiterated RatingBuy$42.00 ➝ $70.00High
6/3/2019Credit Suisse GroupInitiated CoverageUnderperform ➝ Underperform$14.00High
6/3/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$42.00High
6/3/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$28.00High
6/3/2019JMP SecuritiesInitiated CoverageMkt Outperform ➝ Mkt Outperform$53.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
7/29/2021
  • 3 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Cortexyme logo
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline comprises COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $93.65
Low: $90.28
High: $94.31

50 Day Range

MA: $83.96
Low: $53.59
High: $120.21

52 Week Range

Now: $93.65
Low: $26.66
High: $121.98

Volume

203,742 shs

Average Volume

266,766 shs

Market Capitalization

$2.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Cortexyme?

The following Wall Street sell-side analysts have issued stock ratings on Cortexyme in the last year: Bank of America Co., Canaccord Genuity, HC Wainwright, Jefferies Financial Group Inc., Smith Barney Citigroup, and Zacks Investment Research.
View the latest analyst ratings for CRTX.

What is the current price target for Cortexyme?

3 Wall Street analysts have set twelve-month price targets for Cortexyme in the last year. Their average twelve-month price target is $128.00, suggesting a possible upside of 36.7%. HC Wainwright has the highest price target set, predicting CRTX will reach $200.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $34.00 for Cortexyme in the next year.
View the latest price targets for CRTX.

What is the current consensus analyst rating for Cortexyme?

Cortexyme currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRTX, but not buy more shares or sell existing shares.
View the latest ratings for CRTX.

What other companies compete with Cortexyme?

How do I contact Cortexyme's investor relations team?

Cortexyme's physical mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 910-5717 and its investor relations email address is [email protected] The official website for Cortexyme is www.cortexyme.com.